Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis

Bone

Volumn 76, Issue , 2015, Pages 141-148

  Chen, Hui ^a,d   Xu, Xinchen ^a   Liu, Min ^b   Zhang, Wen ^c   Ke, Hua zhu ^b   Qin, An ^a   Tang, Tingting ^a   Lu, Eryi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b AMGEN INC   (United States)

^c SOOCHOW UNIVERSITY   (China)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bone anabolic agent; Estrogen deficiency osteopenia; Periodontitis; Sclerostin antibody

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANABOLIC AGENT; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; MONOCLONAL ANTIBODY; OSTEOCALCIN; OSTEOPROTEGERIN; SCLEROSTIN NEUTRALIZING MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; NEUTRALIZING ANTIBODY; SOST PROTEIN, RAT;

ALVEOLAR BONE; ALVEOLAR CREST HEIGHT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE MASS; BONE VOLUME FRACTION; CHEMICAL LABELING; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; MICRO-COMPUTED TOMOGRAPHY; MINERAL APPOSITION RATE; MINERALIZING SURFACE BONE SURFACE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PERIODONTITIS; PROTEIN BLOOD LEVEL; RAT; TOOTH CERVIX; ANIMAL; BLOOD; BONE DENSITY; DISEASE MODEL; GENETIC MARKER; IMMUNOLOGY; OVARIECTOMY; PATHOLOGY; RADIOGRAPHY; SPRAGUE DAWLEY RAT;

ALVEOLAR PROCESS; ANIMALS; ANTIBODIES, NEUTRALIZING; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC MARKERS; OSTEOCALCIN; OSTEOPROTEGERIN; OVARIECTOMY; PERIODONTITIS; RATS; RATS, SPRAGUE-DAWLEY; X-RAY MICROTOMOGRAPHY;

EID: 84928011338     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.04.002     Document Type: Article

References (36)

1. Di Benedetto A., Gigante I., Colucci S., Grano M. Periodontal disease: linking the primary inflammation to bone loss. Clin Dev Immunol 2013, 2013:503754.
2. Xu X.C., Chen H., Zhang X., Zhai Z.J., Liu X.Q., Qin A., et al. Simvastatin prevents alveolar bone loss in an experimental rat model of periodontitis after ovariectomy. J Transl Med 2014, 12:284.
3. Thornton-Evans G., Eke P., Wei L., Palmer A., Moeti R., Hutchins S., et al. Periodontitis among adults aged ≥30years-United States, 2009-2010. MMWR Surveill Summ 2013, 62(Suppl. 3):129-135.
4. Brennan-Calanan R.M., Genco R.J., Wilding G.E., Hovey K.M., Trevisan M., Wactawski-Wende J. Osteoporosis and oral infection: independent risk factors for oral bone loss. J Dent Res 2008, 87:323-327.
5. Bartold P.M., Cantley M.D., Haynes D.R. Mechanisms and control of pathologic bone loss in periodontitis 2010, 56-69. Periodontol 2000.
6. Aufdemorte T.B., Fox W.C., Miller D., Buffum K., Holt G.R., Carey K.D. A non-human primate model for the study of osteoporosis and oral bone loss. Bone 1993, 14:581-586.
7. Guiglia R., Di Fede O., Lo Russo L., Sprini D., Rini G.B., Campisi G. Osteoporosis, jawbones and periodontal disease. Med Oral Patol Oral Cir Bucal 2013, 18:e93-e99.
8. Taut A.D., Jin Q., Chung J.H., Galindo-Moreno P., Yi E.S., Sugai J.V., et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res 2013, 28:2347-2356.
9. Bashutski J.D., Eber R.M., Kinney J.S., Benavides E., Maitra S., Braun T.M., et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010, 363:2396-2405.
10. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887.
11. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280:26770-26775.
12. Agholme F., Li X., Isaksson H., Ke H.Z., Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010, 25:2412-2418.
13. Li X., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., Grisanti M., et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010, 25:2647-2656.
14. Eddleston A., Marenzana M., Moore A.R., Stephens P., Muzylak M., Marshall D., et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009, 24:1662-1671.
15. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
16. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
17. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
18. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
19. Park C.H., Abramson Z.R., Taba M., Jin Q., Chang J., Kreider J.M., et al. Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol 2007, 78:273-281.
20. Ke H.Z., Richards W.G., Li X., Ominsky M.S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012, 33:747-783.
21. Esfahanian V., Shamami M.S., Shamami M.S. Relationship between osteoporosis and periodontal disease: review of the literature. J Dent 2012, 9:256-264.
22. Wactawski-Wende J. Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol 2001, 6:197-208.
23. Tezal M., Wactawski-Wende J., Grossi S.G., Ho A.W., Dunford R., Genco R.J. The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000, 71:1492-1498.
24. Horvath A., Mardas N., Mezzomo L.A., Needleman I.G., Donos N. Alveolar ridge preservation. A systematic review. Clin Oral Investig 2013, 17:341-363.
25. Wactawski-Wende J., Hausmann E., Hovey K., Trevisan M., Grossi S., Genco R.J. The association between osteoporosis and alveolar crestal height in postmenopausal women. J Periodontol 2005, 76(Suppl. 11):S2116-S2124.
26. Bottino M.C., Thomas V., Schmidt G., Vohra Y.K., Chu T.M., Kowolik M.J., et al. Recent advances in the development of GTR/GBR membranes for periodontal regeneration-a materials perspective. Dent Mater 2012, 28:703-721.
27. Polimeni G., Koo K.T., Qahash M., Xiropaidis A.V., Albandar J.M., Wikesjo U.M. Prognostic factors for alveolar regeneration: effect of tissue occlusion on alveolar bone regeneration with guided tissue regeneration. J Clin Periodontol 2004, 31:730-735.
28. Scantlebury T.V. 1982-1992: A decade of technology development for guided tissue regeneration. J Periodontol 1993, 64(Suppl. 11):S1129-S1137.
29. Li X., Ominsky M.S., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011, 152:3312-3322.
30. Stolina M., Dwyer D., Niu Q.T., Villasenor K.S., Kurimoto P., Grisanti M., et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone 2014, 67:305-313.
31. Ominsky M.S., Niu Q.T., Li C., Li X., Ke H.Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 2014, 29:1424-1430.
32. Hildebolt C.F., Pilgram T.K., Yokoyama-Crothers N., Vannier M.W., Dotson M., Muckerman J., et al. The pattern of alveolar crest height change in healthy postmenopausal women after 3years of hormone/estrogen replacement therapy. J Periodontol 2002, 73:1279-1284.
33. Hildebolt C.F., Pilgram T.K., Yokoyama-Crothers N., Vannier M.W., Dotson M., Muckerman J., et al. Alveolar bone height and postcranial bone mineral density: negative effects of cigarette smoking and parity. J Periodontol 2000, 71:683-689.
34. Payne J.B., Reinhardt R.A., Nummikoski P.V., Patil K.D. Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 1999, 10:34-40.
35. Weinmann J.P. Progress of gingival inflammation into the supporting structures of the teeth. J Periodontol 1941, 12:71-81.
36. Chen H., Liu N., Xu X., Qu X., Lu E. Smoking, radiotherapy, diabetes and osteoporosis as risk factors for dental implant failure: a meta-analysis. PLoS One 2013, 8:e71955.